DENDRITIC CELLS (DC) are the key ANTIGEN PRESENTING CELLS (APC) of the immune system.

They are the cells that INITIATE, DIRECT and REGULATE the immune responses.

 

DENVAX

The DENVAX is dendritic cell-based cancer immunotherapy for solid cancers in various stages of the disease. It is autologous treatment, which involves patient's own mononuclear cells transformed into cancer-specific dendritic cells.

Designed to be specific, DENVAX targets only the cancer cells without harming the healthy ones. It is safe and effective and works best to prevent relapse and recurrences, the major cause of mortality and morbidity.

DENVAX helps in correcting the failed immune surveillance and teaches the immune system to recognize and kill cancer cells.

Why do cancers relapse?

A cancer relapse occurs because in spite of the best efforts to get rid of cancer, some cancer cells are left behind. These cancer cells remain dormant for a period of time, but eventually they continue to multiply resulting in the recurrence or relapse.

What is the best way to treat relapse?

Cancer treatment modalities like surgical resection, chemotherapy and/or radiation are mostly ineffective in controlling the micrometastasis. Micrometastases are single tumor cells or clusters of cells shed by solid cancers and disseminated in various organs of the body. Micrometastases have a pronounced clinical effect, are hard to detect and can be the starting point of recurrence of cancer.

DENVAX targets the micrometastais and destroys the disseminated cancer cells, thereby preventing its development, slowing the spread of cancer and improving the life expectancy.

The ICT welcomes Dr. V. R. Pai on our panel of Oncology as Chief Medical Oncologist

Rockefeller University scientist Ralph Steinman, honored with Nobel Prize for discovery of dendritic cells, died on September 30, 2011, at the age of 68. He suffered from pancreatic cancer.

Rockefeller University cell biologist Ralph M. Steinman who discovered the immune system’s sentinel dendritic cells and demonstrated that science can fruitfully harness the power of these cells and other components of the immune system to curb infections and other communicable diseases, is this year’s recipient of the Nobel Prize in Physiology or Medicine, the Nobel Foundation in Stockholm, Sweden, announced today. He shares the prize with Bruce A. Beutler and Jules A. Hoffmann.

Steinman passed away on September 30. He was 68. He was diagnosed with pancreatic cancer four years ago and his life was extended using a combination of surgery, standard chemotherapy and experimental dendritic-cell based immunotherapy of his own design. Although the Nobel prize is not typically awarded posthumously, the Nobel committee has announced that Dr. Steinman's selection will stand since the committee did not learn of his death until after it had reached its decision.

ICT Mission

• To individualize each treatment plan and provide comprehensive treatment in cancer to help them overcome their disease;
• To help patients achieve complete remission and prevent relapses by initiating treatment at the right time, when tumor load is minimal;
• To provide the highest quality of cell therapy at lowest prices, to make the treatment affordable to a large number of patients.